GH Research (GHRS) Cash from Investing Activities (2021 - 2025)
GH Research (GHRS) posted quarterly Cash from Investing Activities of $8.8 million for Q4 2025, down 58.56% year-over-year from $21.3 million in Q4 2024, and down 9.65% quarter-over-quarter from $9.8 million in Q3 2025.
GH Research (GHRS) Cash from Investing Activities (2021 - 2025) Analysis & Trends
GH Research's Cash from Investing Activities history runs 5 years deep, the most recent figure standing at $8.8 million for Q4 2025.
- In Q4 2025, Cash from Investing Activities fell 58.56% year-over-year to $8.8 million; the TTM figure through Dec 2025 stood at $46.2 million (down 29.11% YoY), while the FY2025 annual figure was $46.2 million, down 29.11% from the prior year.
- Cash from Investing Activities for Q4 2025 stood at $8.8 million, down from $9.8 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $21.3 million in Q4 2024, with the low at -$84.6 million in Q4 2022.
- The 5-year median for Cash from Investing Activities is -$12000.0 (2021), against an average of -$1.4 million.
- The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities slumped 540120.0% in 2023, then soared 191150.0% in 2024.
- GH Research's Cash from Investing Activities stood at -$19000.0 in 2021, then sank by 445368.42% to -$84.6 million in 2022, then soared by 99.97% to -$24000.0 in 2023, then soared by 88979.17% to $21.3 million in 2024, then tumbled by 58.56% to $8.8 million in 2025.
- Business Quant data shows GHRS's Cash from Investing Activities at $8.8 million in Q4 2025, $9.8 million in Q3 2025, and $15.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -1.66 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -49.35 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 19.77 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -229.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -363.46 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 24.51 Mn |
| 10 | GH Research | 2.02 Bn | 1.68 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.84 Mn |
| Dec 31, 2025 | 8.84 Mn |
| Sep 30, 2025 | 9.78 Mn |
| Sep 30, 2025 | 9.78 Mn |
| Jun 30, 2025 | 15.71 Mn |
| Jun 30, 2025 | 15.71 Mn |
| Mar 31, 2025 | 11.84 Mn |
| Mar 31, 2025 | 11.84 Mn |
| Dec 31, 2024 | 21.33 Mn |
| Dec 31, 2024 | 21.33 Mn |
| Sep 30, 2024 | 15.28 Mn |
| Sep 30, 2024 | 15.28 Mn |
| Jun 30, 2024 | 19.73 Mn |
| Jun 30, 2024 | 19.73 Mn |
| Mar 31, 2024 | 8.79 Mn |
| Mar 31, 2024 | 8.79 Mn |
| Dec 31, 2023 | -24,000.00 |
| Dec 31, 2023 | -24,000.00 |
| Sep 30, 2023 | -8,000.00 |
| Sep 30, 2023 | -8,000.00 |